Clinical Trials
65 trialsA Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
Massachusetts General Hospital
Testing the Addition of the Anti-cancer Viral Therapy Telomelysinâ„¢ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery
NRG Oncology
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
National Cancer Institute (NCI)
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
Rutgers, The State University of New Jersey
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer
University of California, San Diego
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
Ohio State University Comprehensive Cancer Center
Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer
University of Kentucky
FORTITUDE-201
Amgen
A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
Health Hope Pharma
MK-3475 Immunotherapy in Endometrial Carcinoma
Washington University School of Medicine
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche
Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
University of Oklahoma
Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors
Avera McKennan Hospital & University Health Center
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
EMD Serono
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Roswell Park Cancer Institute
MK-4440-001
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors
Takeda
Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
Ipsen
MK-3475-434
Merck Sharp & Dohme LLC
A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors
Takeda
A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel
Athenex, Inc.
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
Bristol-Myers Squibb
MK-3475-011
Merck Sharp & Dohme LLC
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
Fox Chase Cancer Center
KEYNOTE 173
Merck Sharp & Dohme LLC
Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
Daiichi Sankyo
CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
Daiichi Sankyo
Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors
Takeda
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies
Takeda
A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
Takeda
A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors
Takeda
MK-2206-003
Merck Sharp & Dohme LLC
A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
Dana-Farber Cancer Institute
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
Tracon Pharmaceuticals Inc.
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
GlaxoSmithKline
Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
Takeda
The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
AstraZeneca
Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
Takeda
14C
AstraZeneca
Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours
AstraZeneca
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
Takeda
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
Boehringer Ingelheim
Study Evaluating Safety And Tolerability, Solid Tumor
Puma Biotechnology, Inc.
Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
Ohio State University Comprehensive Cancer Center
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
MedImmune LLC